Scroll for more

news

featured

May 25, 2017 announcements

AI enabled research shows delay in onset of motor neurone disease

Sheffield and London, UK - 25 May 2017.  The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.

Recent

Jun 15, 2017 articles

BenevolentAI: drug research startup goes on hiring spree as UK’s artificial intelligence sector booms

Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.

Apr 25, 2017 articles

A British tech unicorn is trying to cure Alzheimer's and ALS with artificial intelligence

Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.

Feb 21, 2017 articles

Bold claims for AI are hard to compute for economists

The Financial Times takes a look at the work we’re doing at BenevolentAI to “revolutionise medical research” after speaking to Co-Founder and Director, Ken Mulvany.